comparemela.com

Latest Breaking News On - Prnewswire pneumagen - Page 1 : comparemela.com

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

- Neumifil is a novel broad-spectrum anti-viral product that was shown to be well-tolerated with no safety signals at all doses tested - Pneumagen plans to conduct a Phase 2 Influenza challenge

United kingdomFrazer hallPrnewswire pneumagenKostenloser wertpapierhandelGeoff kitsonDouglas thomsonEvelyn mccormackSandi greenwoodUniversity of st andrewsChief medical officerRespiratory syncytial virusDavid dibleCarbohydrate binding moleculeInfluenza virus

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a novel intranasal spray which is designed to provide patients at risk with an.

South africaUnited kingdomCity ofSouth africanJohn beadleFrazer hallPrnewswire pneumagenDouglas thomsonJohn beadleaddedSandi greenwoodLondon business schoolPsioxus therapeutics ltdAfrican college of medicineEntrepreneur in residence at imperial collegeUniversity of st andrewsUniversity of the witwatersrand

Pneumagen Raises £3 8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

ST ANDREWS, Scotland, Jan. 19, 2022 /PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral

United kingdomCity ofCathal frielFrazer hallPrnewswire pneumagenThairm bioThairm bio mark bamforthPneumagen neumifilDouglas thomsonSandi greenwoodUniversity of st andrewsVenn life sciencesOpen orphanMark bamforthGrowth investmentsScottish enterprise

vimarsana © 2020. All Rights Reserved.